Search research articles
Contact Us
Filters
Showing results (81-90 of 100) with videos related to
Page
of 10
Sort By:
Journal of Dermatological Science
|
January 23, 2023
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study
Andrew Blauvelt, David M Pariser, Stephen Tyring, et al.
Archives of Dermatology
|
February 21, 2007
National Psoriasis Foundation clinical consensus on disease severity
David M Pariser, Jerry Bagel, Joel M Gelfand, et al.
Immunotherapy
|
May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary
Bruce Strober, Diamant Thaçi, Howard Sofen, et al.
Dermatology and Therapy
|
October 26, 2025
Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16
Eingun James Song, Benjamin Ehst, Brad Glick, et al.
Journal of the American Academy of Dermatology
|
September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
Bruce Strober, Diamant Thaçi, Howard Sofen, et al.
The Journal of Dermatological Treatment
|
June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Neil J Korman, Richard B Warren, Jerry Bagel, et al.
Current Medical Research and Opinion
|
December 3, 2024
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry
Michael A Haft, Keith D Knapp, Ami Claxton, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
February 19, 2025
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry
Dawn Z Eichenfield, Keith D Knapp, Ami Claxton, et al.
The British Journal of Dermatology
|
July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
The New England Journal of Medicine
|
December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Mark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 100) with videos related to
Sort By:
Page
of 10
Journal of Dermatological Science
|
January 23, 2023
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study
Andrew Blauvelt, David M Pariser, Stephen Tyring, et al.
Archives of Dermatology
|
February 21, 2007
National Psoriasis Foundation clinical consensus on disease severity
David M Pariser, Jerry Bagel, Joel M Gelfand, et al.
Immunotherapy
|
May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary
Bruce Strober, Diamant Thaçi, Howard Sofen, et al.
Dermatology and Therapy
|
October 26, 2025
Efficacy and Safety of Risankizumab in Genital or Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16
Eingun James Song, Benjamin Ehst, Brad Glick, et al.
Journal of the American Academy of Dermatology
|
September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
Bruce Strober, Diamant Thaçi, Howard Sofen, et al.
The Journal of Dermatological Treatment
|
June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Neil J Korman, Richard B Warren, Jerry Bagel, et al.
Current Medical Research and Opinion
|
December 3, 2024
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry
Michael A Haft, Keith D Knapp, Ami Claxton, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
February 19, 2025
Unmet Needs of Effective Advanced Systemic Therapies in Moderate-to-Severe Atopic Dermatitis Patients in the TARGET-DERM AD Registry
Dawn Z Eichenfield, Keith D Knapp, Ami Claxton, et al.
The British Journal of Dermatology
|
July 25, 2023
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)
Linda F Stein Gold, Jerry Bagel, Stephen K Tyring, et al.
The New England Journal of Medicine
|
December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Mark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
Page
of 10